logo-loader

Immupharma updates on successful placing

Published: 14:46 24 Feb 2016 GMT

Pounds-coins-notes-(Resized)
It has applied to HMRC to receive VCT Advance Assurance and / or EIS Advance Assurances to raise the further £0.7mln but these must be obtained no later than March 23..

Drug discovery firm ImmuPharma (LON:IMM) has  raised £7.7mln from the previously announced fundraise and is due to receive a further £0.7mln from advance assurances.

It has applied to HMRC to receive VCT Advance Assurance and / or EIS Advance Assurances to raise the further £0.7mln but these must be obtained no later than March 23.

The firm has said the cash will be used to fund its share of the costs of developing Lupuzor, its potential blockbuster drug for the autoimmune disease Lupus, which is currently undergoing phase III clinical trials and also provide the firm with its working capital requirements through to 2018.

Immupharma shares eased 2.08% to 23.5p.

ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug...

ImmuPharma PLC (AIM:IMM) chief executive Tim McCarthy provides an extensive update during an interview with Proactive's Stephen Gunnion, focusing on the financial, business, and portfolio developments of the company. McCarthy clarified that the company is in a strong financial position,...

3 weeks, 1 day ago